Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAF(V600E/K)- mutated melanoma

PURPOSE: Test the hypothesis that in BRAF-mutated melanomas, clinical responses to selumetinib, a MEK inhibitor, will be restricted to tumors in which the PI3K/AKT pathway is not activated. EXPERIMENTAL DESIGN: We conducted a phase II trial in melanoma patients whose tumors harbored a BRAF mutation....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Catalanotti, Federica, Solit, David B., Pulitzer, Melissa P., Berger, Michael F., Scott, Sasinya N., Iyriboz, Tunc, Lacouture, Mario E., Panageas, Katherine S., Wolchok, Jedd D., Carvajal, Richard D., Schwartz, Gary K., Rosen, Neal, Chapman, Paul B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3932005/
https://ncbi.nlm.nih.gov/pubmed/23444215
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-3476
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados